Moleculin Biotech, Inc. announced the appointment of Dr. Sandra Silberman as Chief Medical Officer in charge of New Products. Dr. Silberman's career in clinical development began at Pfizer, Inc., where she oversaw the initiation of Tarceva clinical trials. She then led the global development of Gleevec at Novartis. Sandra was the first Vice President and Global Therapeutic Area Head.